BRPI0906522A2 - Sulfonamidas como antagonistas de orexina - Google Patents

Sulfonamidas como antagonistas de orexina

Info

Publication number
BRPI0906522A2
BRPI0906522A2 BRPI0906522-9A BRPI0906522A BRPI0906522A2 BR PI0906522 A2 BRPI0906522 A2 BR PI0906522A2 BR PI0906522 A BRPI0906522 A BR PI0906522A BR PI0906522 A2 BRPI0906522 A2 BR PI0906522A2
Authority
BR
Brazil
Prior art keywords
sulfonamides
orexin antagonists
orexin
antagonists
disorders
Prior art date
Application number
BRPI0906522-9A
Other languages
English (en)
Inventor
Henner Knust
Matthias Nettekoven
Emmanuel Pinard
Olivier Roche
Mark Rogers-Evans
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0906522A2 publication Critical patent/BRPI0906522A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
BRPI0906522-9A 2008-01-21 2009-01-12 Sulfonamidas como antagonistas de orexina BRPI0906522A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08150435 2008-01-21
PCT/EP2009/050272 WO2009092642A1 (en) 2008-01-21 2009-01-12 Sulfonamides as orexin antagonists

Publications (1)

Publication Number Publication Date
BRPI0906522A2 true BRPI0906522A2 (pt) 2015-07-14

Family

ID=40551459

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906522-9A BRPI0906522A2 (pt) 2008-01-21 2009-01-12 Sulfonamidas como antagonistas de orexina

Country Status (12)

Country Link
US (1) US7932269B2 (pt)
EP (1) EP2245006B1 (pt)
JP (1) JP5220870B2 (pt)
KR (1) KR101178658B1 (pt)
CN (1) CN101918359B (pt)
AT (1) ATE511500T1 (pt)
AU (1) AU2009207750B2 (pt)
BR (1) BRPI0906522A2 (pt)
CA (1) CA2709050C (pt)
ES (1) ES2364806T3 (pt)
IL (1) IL206359A (pt)
WO (1) WO2009092642A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2962649A1 (fr) 2010-07-19 2012-01-20 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
JP6346862B2 (ja) 2012-02-07 2018-06-20 エオラス セラピューティクス, インコーポレイテッド オレキシンレセプターアンタゴニストとしての置換プロリン/ピペリジン
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
MX2016007661A (es) * 2013-12-12 2017-01-06 Univ Tsukuba Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo.
EP3180332B1 (en) 2014-08-13 2021-10-27 Eolas Therapeutics Inc. Difluoropyrrolidines as orexin receptor modulators
WO2016133160A1 (ja) * 2015-02-19 2016-08-25 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
WO2016199906A1 (ja) * 2015-06-12 2016-12-15 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
BR112018016446B1 (pt) 2016-02-12 2024-02-06 Eolas Therapeutics, Inc. Composto de piperidina halo-substituída, composição farmacêutica compreendendo dito composto e uso terapêutico dos mesmos
WO2018164192A1 (ja) * 2017-03-08 2018-09-13 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
US11059780B2 (en) 2017-03-08 2021-07-13 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
US11319286B2 (en) 2017-08-03 2022-05-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155333A0 (en) * 2000-10-17 2003-11-23 Applied Res Sulfanilide derivatives for use in medicine, certain such new derivatives and their preparation
BR0315115A (pt) * 2002-10-11 2005-08-16 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, método para tratar ou prevenir doenças ou distúrbios em que se requer um antagonista de receptores de orexina humana, processo para a fabricação de composições farmacêuticas, e, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
CA2617324A1 (en) * 2005-08-04 2007-02-15 Merck & Co., Inc. Aminoethane sulfonamide orexin receptor antagonists
US8003654B2 (en) * 2006-04-11 2011-08-23 Actelion Pharmaceuticals Ltd. N-glycinsulfonamide derivatives and uses as orexin receptor antagonists

Also Published As

Publication number Publication date
IL206359A (en) 2014-06-30
ES2364806T3 (es) 2011-09-14
JP5220870B2 (ja) 2013-06-26
JP2011510037A (ja) 2011-03-31
EP2245006A1 (en) 2010-11-03
KR20100092979A (ko) 2010-08-23
EP2245006B1 (en) 2011-06-01
AU2009207750A1 (en) 2009-07-30
CN101918359A (zh) 2010-12-15
AU2009207750B2 (en) 2013-03-14
CA2709050A1 (en) 2009-07-30
CA2709050C (en) 2016-06-14
US7932269B2 (en) 2011-04-26
WO2009092642A1 (en) 2009-07-30
CN101918359B (zh) 2013-02-27
US20090186920A1 (en) 2009-07-23
ATE511500T1 (de) 2011-06-15
IL206359A0 (en) 2010-12-30
KR101178658B1 (ko) 2012-08-30

Similar Documents

Publication Publication Date Title
BRPI0906522A2 (pt) Sulfonamidas como antagonistas de orexina
CY1119515T1 (el) Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης
CY1119218T1 (el) Αναστολεις διυδροπυριδοφθαλαζινονης της πολυμερασης της πολυαδενοσφωσφορικης ριβοζης (parp)
DE602007012072D1 (de) Orantagonisten
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
EA201270149A1 (ru) Ингибиторы bace
EA201170884A1 (ru) Производные пиперидина, пригодные в качестве антагонистов орексина
ATE500250T1 (de) Azetidinverbindungen als orexin-rezeptor- antagonisten
MA32939B1 (fr) Composes organiques
ECSP11010885A (es) Heteroarilos sustituidos
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
EA200970666A1 (ru) Трициклические соединения, композиции и способы
BRPI0813966A8 (pt) Usos de mdl-1
UY32384A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
UA106873C2 (uk) Сполуки заміщених діазепанів як антагоністи орексинових рецепторів
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
BRPI0916657A2 (pt) pirrolidin-3-ilmetil-amina como antagonistas de orexina
CU20100115A7 (es) Intermedios útiles para la preparación de derivados de carboxamida como antagonistas del receptor muscarínico
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
EA201290558A1 (ru) Агонисты mglu2
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
EA201270255A1 (ru) 5-фтор-2-оксопиримидин-1(2h)-карбоксилатные производные
EA201170585A1 (ru) Производные изохинолинона в качестве антагонистов nk3

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements